Research programme: PPAR agonists - Bayer

Drug Profile

Research programme: PPAR agonists - Bayer

Alternative Names: PPAR alpha/gamma/delta agonists - Bayer; PPAR gamma/delta agonists - Bayer

Latest Information Update: 25 Mar 2010

Price : $50

At a glance

  • Originator Bayer
  • Class
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Metabolic syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 25 Mar 2010 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (PO)
  • 25 Mar 2010 Discontinued - Preclinical for Metabolic syndrome in USA (PO)
  • 26 Sep 2006 Preclinical trials in Metabolic syndrome in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top